Dosing

TREMFYA® DOSING IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
A SINGLE, 100 MG DOSE ONCE EVERY 8 WEEKS AFTER ONLY 2 STARTER DOSES1

FREQUENCY OF INJECTIONS FOR SUBCUTANEOUS (SC) BIOLOGICS (FIRST 52 WEEKS) IN ADULTS

*Based on the recommended 300 mg dose. 150 mg may be acceptable for some patients.

†In addition to the 50 mg, twice-weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. The proportion of responders was related to Enbrel® dosage.

This presentation is not intended to compare the relative safety or efficacy of these treatments. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product's Prescribing Information for additional information.

STELARA® is indicated for the treatment of patients 12 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up visits with a physician. In adolescent patients, it is recommended that STELARA® be administered by a healthcare provider. If a physician determines that is is appropriate, a patient may self-inject or a caregiver may inject STELARA® after proper training in subcutaneous injection technique. Patients should be instructed to follow the directions provided in the Medication Guide. View the Important Safety Information for STELARA®.
Taltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Humira® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Siliq™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Cosentyx® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
Indicated trademarks are registered trademarks of their respective owners.

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

References: 1. TREMFYA® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 2. STELARA® (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 3. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 4. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 5. Siliq™ (brodalumab) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC. 6. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 7. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation.